Table 1

Baseline demographics, scleroderma related organ system involvement and previous treatments

Parameter
Age, in years, median (range)
 Median48
 Minimum, maximum18, 71
Sex, n (%)
 Women24 (80%)
 Men6 (20%)
Race, ethnicity, n (%)
 White, non-Hispanic22 (73%)
 White, Hispanic4 (13%)
 African-American4 (13%)
Disease duration, n, mean±SD
 Whole group, n=303.4±2.3 years
 Early group, n=20 (0–4 years)2.1±1.2 years
 Later group, n=10 (4–10 years)6.1±1.6 years
Anti-Scl70 positive, n (%)9 (30%)
MRSS at baseline30.3±8.7
Organ involvement, n (%)
 Gastrointestinal28 (93%)
 ILD16 (53%)
 Pulmonary artery Hypertension3 (10%)
 Cardiac3 (10%)
 Renal1 (3%)
 Myopathy10 (33%)
 Arthritis22 (73%)
 Raynaud's phenomenon30 (100%)
 Digital ulceration24 (80%)
Previous treatment, n (%)
 Corticosteroids14 (46.7%)
 Methotrexate9 (30.0%)
 Mycophenalate mofetil6 (20.0%)
 Cyclophosphamide5 (16.7%)
 Penicillamine3 (10.0%)
 IVIG3 (10.0%)
 Plaquenil4 (13.3%)
 Colchicine2 (6.7%)
 Thalidomide2 (6.7%)
 Minocycline2 (6.7%)
 Autologous stem cell transplant1 (3.3%)
 Oral collagen1 (3.3%)
 Phototherapy3 (10%)
 No previous treatment7 (23.3%)
  • ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; MRSS, modified Rodnan skin score.